- Hanmi Pharmaceutical's BH3120, a novel dual-targeting immunotherapy, is progressing through Phase 1 trials, demonstrating a favorable safety profile in advanced solid tumor patients.
- Hanmi Pharmaceutical's BH3120, a novel dual-targeting antibody, is progressing through Phase 1 trials, showing no dose-limiting toxicities in advanced solid tumor patients.
- Hanmi Pharmaceutical has entered a Clinical Trial Collaboration and Supply Agreement with MSD to evaluate its novel immunotherapy BH3120 in combination with KEYTRUDA for patients with progressive or metastatic solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.